You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Disitamab vedotin

Showing 51 - 75 of 280
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +8 more
  • Polatuzumab Vedotin
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma Trial in United States (brentuximab vedotin)

Terminated
  • Hodgkin Lymphoma
  • +2 more
  • brentuximab vedotin
  • Anaheim, California
  • +18 more
Dec 6, 2022

Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Richter's Transformation
  • Boston, Massachusetts
  • +1 more
Sep 12, 2023

Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer Trial in Kansas City (Enfortumab vedotin)

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +2 more
  • Enfortumab vedotin
  • Kansas City, Kansas
    University of Kansas Cancer Center
Jun 23, 2023

Advanced Classical Hodgkin's Lymphoma in Brazil Treated With

Not yet recruiting
  • Hodgkin Lymphoma
  • No Intervention
  • Salvador, Bahia, Brazil
  • +5 more
Oct 23, 2023

Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic

Recruiting
  • Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
  • +3 more
  • Cabozantinib S-malate
  • +3 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Aug 8, 2022

Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter Trial in

Recruiting
  • Urothelial Cancer
  • +3 more
  • Sacituzumab Govitecan (SG)
  • Enfortumab vedotin-ejfv (EV)
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 28, 2022

Leukemia Trial in Houston (Brentuximab Vedotin, 5-Azacytidine)

Terminated
Has Results
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 7, 2022

Post-transplant Lymphoproliferative Disorder Trial in Saint Louis (Polatuzumab vedotin, Rituximab, CHP)

Not yet recruiting
  • Post-transplant Lymphoproliferative Disorder
  • Polatuzumab vedotin
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Sep 9, 2023

AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in France, United

Active, not recruiting
  • AIDS-Related Hodgkin Lymphoma
  • +11 more
  • Brentuximab Vedotin
  • +4 more
  • La Jolla, California
  • +27 more
Jul 27, 2022

Brentuximab Vedotin in Adults With CD30-positive Lymphoma

Recruiting
  • Lymphoma
  • No Intervention
  • Hefei, Anhui, China
  • +25 more
Jul 14, 2022

Non Small Cell Lung Cancer Trial in Worldwide (Telisotuzumab Vedotin, Docetaxel)

Recruiting
  • Non Small Cell Lung Cancer
  • Los Angeles, California
  • +212 more
Jan 26, 2023

Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III

Recruiting
  • Ann Arbor Stage III Hodgkin Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • +9 more
  • Birmingham, Alabama
  • +731 more
Aug 24, 2022

Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

Recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2022

Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell

Recruiting
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • Pembrolizumab
  • Chicago, Illinois
    Northwestern University
Jun 15, 2022

Reporting of Antibody-Drug Conjugate Associated Sepsis-related

Completed
  • Sepsis (SMQ)
  • +2 more
  • Antibody-Drug Conjugate
  • Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
  • Changsha, Hunan, China
    Central South University
Jun 19, 2022

Brentuximab Vedotin in Pediatric Hodgkin Lymphoma

Not yet recruiting
  • Hodgkin Lymphoma
  • Brentuximab Vedotin
  • (no location specified)
Jul 28, 2022

NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Telisotuzumab Vedotin
  • +4 more
  • (no location specified)
Oct 17, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Aug 23, 2022

T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

Withdrawn
  • T Cell Lymphoma
  • Brentuximab Vedotin
  • Kansas City, Kansas
    The University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023

Peripheral T-cell Lymphoma Trial in Worldwide (brentuximab vedotin, cyclophosphamide, doxorubicin)

Recruiting
  • Peripheral T-cell Lymphoma
  • brentuximab vedotin
  • +3 more
  • Birmingham, Alabama
  • +45 more
Jan 4, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab Vedotin, Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Large B-Cell Lymphoma Trial in Xi'an (Glofitamab, Polatuzumab vedotin, Rituximab)

Not yet recruiting
  • Large B-Cell Lymphoma
  • Xi'an, China
    First Affiliated Hospital of Medical College of Xi'an Jiaotong U
Sep 14, 2023

Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter

Recruiting
  • Locally Advanced Bladder Urothelial Carcinoma
  • +18 more
  • Los Angeles, California
  • +2 more
Jun 28, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023